SCHEMBL19199355

SCHEMBL19199355

CCOC(=O)C(C)S(C)(C)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.47
TSHR P16473 3/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
NPC1 O15118 1/20 0.46
ATM Q13315 1/20 0.44
MMP8 P22894 2/20 0.44
TDP1 Q9NUW8 1/20 0.43
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
POLB P06746 2/20 0.42
HSD11B1 P28845 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19199769 1.00 PIN1 (0.47) PIN1TSHRKMT2AMEN1NPC1
SCHEMBL19199568 0.86 KMT2A (0.45) TSHRKMT2AMEN1LMNAL3MBTL1
SCHEMBL19199783 0.86 KMT2A (0.45) TSHRKMT2AMEN1LMNAL3MBTL1
SCHEMBL19199856 0.85 KMT2A (0.51) TSHRKMT2ATDP1LMNAMAPT
SCHEMBL19200097 0.85 KMT2A (0.51) TSHRKMT2ATDP1LMNAMAPT
SCHEMBL19199740 0.83 LMNA (0.49) TSHRKMT2AMEN1NPC1LMNA
SCHEMBL19199749 0.83 POLB (0.49) TSHRKMT2AMEN1NPC1ATM
SCHEMBL19199827 0.83 LMNA (0.49) TSHRKMT2AMEN1NPC1LMNA
SCHEMBL19200664 0.83 POLB (0.49) TSHRKMT2AMEN1NPC1ATM
SCHEMBL19199833 0.83 LMNA (0.64) LMNAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10927355-B2 Method for producing an organosilicon product CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2021-02-23 US disclosed
US-20170218346-A1 Heme Protein Catalysts for Carbon-Silicon Bond Formation In Vitro and In Vivo CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2017-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10927355-B2 Method for producing an organosilicon product HMOX2, HMOX1, HMBS PIN1 57/4885TSHR 4561/4885KMT2A 3909/4885
US-20170218346-A1 Heme Protein Catalysts for Carbon-Silicon Bond Formation In Vitro and In Vivo HMOX2, HMOX1, HCCS PIN1 79/4885TSHR 4669/4885KMT2A 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.